FOLD Quote, Financials, Valuation and Earnings

Insmed has a net margin of 9.85% compared to Amicus Therapeutics's net margin of -225.53%. Amicus Therapeutics's return on equity of -35.23% beat Insmed's return on equity of -41989.34%.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 142.78%. On the other hand Insmed has an analysts' consensus of $95.78 which suggests that it could grow by 41.61%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

Amicus Therapeutics has a beta of 0.795, which suggesting that the stock is 20.519% less volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are larger than Insmed quarterly revenues of $104.4M. Amicus Therapeutics's net income of $14.7M is higher than Insmed's net income of -$235.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.97x versus 30.50x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 9.85% compared to Amicus Therapeutics's net margin of -49.65%. Amicus Therapeutics's return on equity of -35.23% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 142.78%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 69.97%. Given that Amicus Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than NovaBay Pharmaceuticals.

Amicus Therapeutics has a beta of 0.795, which suggesting that the stock is 20.519% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Amicus Therapeutics's net income of $14.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.97x versus 0.13x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of 9.85% compared to Amicus Therapeutics's net margin of -9.24%. Amicus Therapeutics's return on equity of -35.23% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 142.78%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 206.7%. Given that Vanda Pharmaceuticals has higher upside potential than Amicus Therapeutics, analysts believe Vanda Pharmaceuticals is more attractive than Amicus Therapeutics.

Amicus Therapeutics has a beta of 0.795, which suggesting that the stock is 20.519% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are larger than Vanda Pharmaceuticals quarterly revenues of $53.2M. Amicus Therapeutics's net income of $14.7M is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.97x versus 1.21x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 9.85% compared to Amicus Therapeutics's net margin of 31.35%. Amicus Therapeutics's return on equity of -35.23% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Amicus Therapeutics has a consensus price target of $16.73, signalling upside risk potential of 142.78%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.94 which suggests that it could grow by 3.24%. Given that Amicus Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Vertex Pharmaceuticals.

Amicus Therapeutics has a beta of 0.795, which suggesting that the stock is 20.519% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $149.7M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Amicus Therapeutics's net income of $14.7M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.97x versus 11.35x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.